BriaCell Therapeutics (BCTX) Plunges 61.78% After $15M Public Offering

BriaCell Therapeutics (BCTX) experienced a significant decline, with its share price plummeting 61.78% to its lowest level since January 2025, marking an intraday drop of 65.84%.

The strategy of buying BCTX shares after they reached a recent low and holding for one week resulted in a significant loss. Over the past five years, the strategy yielded a return of -97.38%, underperforming the benchmark by 2.62%. The Sharpe ratio was -0.45, indicating substantial risk, while the maximum drawdown was 0%, reflecting the complete loss of investment value.

BriaCell Therapeutics recently announced the pricing of a $15 million public offering on July 15, 2025. This move is part of the company's strategy to secure additional funding for its ongoing research and development efforts. The public offering is expected to provide the necessary capital to support the company's clinical trials and other operational expenses.

In addition to the public offering, BriaCell Therapeutics has made significant progress in its clinical trials. The company has added the Mayo Clinic as a site for its Phase 3 study in metastatic breast cancer. This expansion follows positive Phase 2 survival data, which has shown promising results in treating metastatic breast cancer. The inclusion of the Mayo Clinic, a renowned medical institution, is expected to enhance the credibility and reach of the study, potentially attracting more participants and increasing the likelihood of successful outcomes.

The positive results from previous trials and the expansion of the Phase 3 study to include the Mayo Clinic have generated optimism among investors. These developments could significantly impact investor perception and potentially influence the stock price. The company's efforts to secure additional funding and advance its clinical trials are seen as positive steps towards achieving its long-term goals.